If you’ve suffered from a ligament or joint damage like an ACL tear, MCL tear, meniscus tear, or rotator cuff tear, or if you need knee replacement or shoulder, hip, neck, back, elbow, or any other orthopedic surgeries, we believe that stem cell treatment is a better option than surgery.
- After stem cell treatment, your body repairs and heals itself. You will generate new cartilage and ligaments, giving you the same feel and function you had before the injury.
- You’ll enjoy a faster healing time. Your body only needs to heal the original injury, not the trauma of surgery in addition to the injury.
- Your own original, actual tissue is much better for your body than anything surgery can create.
- You won’t have to take powerful, risky medications to manage your pain as you heal. The more powerful the medicine, the more powerful the side effects – so it’s good to avoid them if you can.
- Best of all, we are using your own body to heal you. There are no side effects.
To learn more, please contact Miami Stem Cell (305) 598-7777 or visit us at: www.stemcellmia.com
Osteoarthritis (OA) is a chronic joint disease that generally occurs worldwide with pain and disability. The progression is slow, and it is mostly diagnosed midlife and often disturbs the knees, hips, feet, hands, and spine. Sex, age, obesity, occupation, and hereditary factors are risk factors that increase the opportunity for OA. Physical examinations involving X-rays and MRI, joint fluid analysis and blood tests are common tools for the diagnosis of OA. Interventions including exercise, manual therapy, lifestyle modification, and medication can help relieve pain and maintain mobility in the affected joints, yet none of the therapies enables the promotion of regeneration of degenerated tissues. Mesenchymal stem cells (MSCs) are a promising source for the treatment of OA due to their multipotency for differentiation into chondrocytes and their ability to modulate the immune system. Herein, we review the pathogenesis and treatment of OA and address the current status of MSCs as a novel potential therapeutic agent in OA treatment.
Osteoarthritis (OA) is a common chronic disease and accounts for major physical pain and disability in older adults. It is assumed to be the fourth leading cause of disability in the world in 2020 . OA consistently influences the knees, hips, hands, feet, and spine . The knee is the most frequently affected site and accounts for almost 85% of the burden of OA worldwide, followed by the hand and hip [3–5]. The particular syndromes of OA encompass chronic pain, stiffness, mobility restriction, and joint tenderness . A number of risk factors such as female sex, age, obesity, genetic factors, and Oxidative stress increase the chances of developing OA . It is growing more prevalent today because of the combined factors of aging, obesity and the increasing numbers of damaged joints, and an estimated 250 million people are affected by this syndrome .
The structural variations in OA include articular cartilage, subchondral bone, ligaments, synovium, and periarticular muscles. The articular cartilage defect is the most obvious syndrome of OA, which is caused by degeneration of the extracellular matrix [8,9]. People diagnosed with OA suffer physical weakness, mental pressure and impaired quality of daily life . Currently, both nonpharmacological methods and pharmacological methods are applied to treat OA. Nonpharmacological methods, including self-management, regular exercise, and weight control, are highly recommended and are regarded as first-line treatments for OA [11,12]. Pharmacological methods recommended in the guidelines are paracetamol and NSAIDs, which are often used when nonpharmacological methods are not able to relieve pain and reduce disability. Patients with hip and knee OA who do not respond to topical analgesics are recommended to take intra-articular corticosteroids . Duloxetine is a serotonin and norepinephrine reuptake inhibitor, which is recommended in some guidelines to reduce the severe pain of OA . New treatments, such as nerve growth factor (NGF) antibodies, have been evaluated and have shown positive results in reducing pain in patients with hip and knee OA . Surgical options such as joint replacement surgery, knee osteotomy, and knee joint distraction are either recommended for patients with late-stage OA or young and energetic patients with moderate radiographic severity in OA [15–17]. However, the above treatments are designed to reduce pain and improve the mobility of joints instead of promoting the regeneration of damaged articular cartilage. The regenerative treatments are intended to repair and replace the injured cells and tissues with new ones. As a regenerative cell therapy of OA, mesenchymal stem cells (MSCs) have the potential of self-renewal and differentiation into cartilage and the capability of immune modulation. A number of preclinical and clinical studies have confirmed the potential for MSCs as a novel therapeutic strategy for the treatment of OA. In this review, we provide an extensive review of the pathogenesis and treatment of OA and emphasize the therapeutic features of bone marrow MSCs (BM-MSCs), adipose tissue-derived MSCs (AD-MSCs), and umbilical cord-derived MSCs (UC-MSCs) in OA treatment ().
To read more, please click on the link below:
Stem cell therapy for knees has the potential to provide relief to a lot of people. Knee pain is an common condition that affects millions of Americans and people around the world. Considering the daily load that legs bear, a problem with your knees can limit movement. Knee pain can substantially reduce your quality of life and anti-inflammatory medication can only do so much. Suffice it to say, there exists significant interest in finding solutions to address knee pain and to restore healthy joint function.
Why Is Stem Cell Therapy For Knees Important?
With the growing power of regenerative medicine, more physicians are now able to offer affordable, cost-effective and – most importantly – long-lasting treatments that address pain in the short and long term. Stem cell therapy for knees carries with it the possibility to make knee joint pain obsolete.
Despite the promise of regenerative therapy, however, it’s still important to perform due diligence before making a decision. This requires understanding some facts about knee pain. These facts include what causes it, how stem cell therapy provides relief, how it works, and who’s a good candidate.
The Prevalence and Problem of Knee Pain
More than a third of Americans suffering from arthritis experience severe joint pain (arthritis), the number rising to 15 million in 2014. A recent Korean study concluded that 46.2% of people over 50 suffered some type of knee pain, of which roughly 32.2 percent are men and 58.0 percent are women.
Unfortunately, treatments are limited. Cortisone injections can cause secondary issues at the site of injection. Patients may suffer joint infection, nerve damage, skin thinning, temporarily greater pain, tendon weakening, bone thinning, and bone death. These are clearly not minimal risks. Other treatments include knee replacement surgery. This also carries all the normal risks of anesthesia and invasive procedures, and anti-inflammatory medications, which are the prevailing cause of acute liver failure in the United States.
One can easily see the appeal of a simple injection. So exactly how does stem cell therapy work? What are recovery times like, what conditions does it treat, and who can get the treatment? These are critical questions to ask before embarking on a course of stem cell therapy. In fact, they should be asked even before setting up a consultation.
For more, click the link below:
Stem Cell Therapy For Knees
‘This is such an important moment’: how stem cell research is transforming medicine
A new documentary shines a light on the breakthroughs that are being made or are close to being made in finding cures to previously incurable diseases.
Ryan Custer was a freshman basketball player at Wright State University in Dayton, Ohio, when, in April 2017, he jumped into a pool at a house party and shattered his C5 vertebra. Paralyzed from the chest down, Custer entered a clinical trial in Chicago for an experimental stem cell therapy that could restore limited nerve function one centimeter – shoulder shrug, bicep motion, tricep use – at a time.
Cheryl Wiers, a mother in her 40s, saw her aggressive non-Hodgkin’s lymphoma return twice, with a vengeance. Chemotherapy wasn’t working, but a clinical trial for a transplant of stem cells at City of Hope medical center in Duarte, California, offered hope.
In San Francisco, Andrew Caldwell, who is HIV-positive, underwent an experimental therapy which transfused his own genetically modified stem cells back into his body; if the modified cells produced enough HIV-resistant fighter cells, known as T-cells, to suppress the virus, the treatment could functionally cure HIV.
All three are vanguards on the slowly unfolding horizon of stem cell therapies, which could offer reprieve from diseases such as certain types of cancers, Type 1 diabetes, lupus and other auto-immune disorders. And all three, along with several others, offer up their emotional, idiosyncratic, and casually radical stories in the film Ending Disease, a collection of intimate portraits of experimental medicine under the culturally fraught, politically vulnerable, and extremely promising umbrella of stem cell research.
Such research has long been a game of potentials – treatments that could cure a host of incurable diseases or conditions, from HIV to certain causes of blindness to quadriplegia; research whose funding could get kneecapped by the whims of political power, treatments that could become available to the masses but are limited to select clinical trial groups. Ending Disease, which followed several trial participants between 2016 and 2019, takes its name from the farthest reaches of said potential: “we are on the cusp of a tremendous number of cures,” said director Joe Gantz.
To read the entire article, please click on the link below:
Basic and clinical research accomplished during the last few years on embryonic, fetal, amniotic, umbilical cord blood, and adult stem cells has constituted a revolution in regenerative medicine and cancer therapies by providing the possibility of generating multiple therapeutically useful cell types. These new cells could be used for treating numerous genetic and degenerative disorders. Among them, age-related functional defects, hematopoietic and immune system disorders, heart failures, chronic liver injuries, diabetes, Parkinson’s and Alzheimer’s diseases, arthritis, and muscular, skin, lung, eye, and digestive disorders as well as aggressive and recurrent cancers could be successfully treated by stem cell-based therapies. This review focuses on the recent advancements in adult stem cell biology in normal and pathological conditions. We describe how these results have improved our understanding on critical and unique functions of these rare sub-populations of multipotent and undifferentiated cells with an unlimited self-renewal capacity and high plasticity. Finally, we discuss some major advances to translate the experimental models on ex vivo and in vivo expanded and/or differentiated stem cells into clinical applications for the development of novel cellular therapies aimed at repairing genetically altered or damaged tissues/organs in humans. A particular emphasis is made on the therapeutic potential of different tissue-resident adult stem cell types and their in vivo modulation for treating and curing specific pathological disorders.
To read more, click below: